Liver Forum 10: NASH regulatory update

Elmer Schabel MD

The views expressed in this presentation are primarily those of the author and do not necessarily express those of the BfArM, nor of the EMA.
Overview

- Current content of the reflection paper regarding trial design
- Regulatory interaction
  - Reflection paper main content/Stakeholder meeting discussion
  - Written Comments on the Reflection Paper
  - Scientific Advice
- Future perspectives
Current content with regard to trial design and endpoints:

- Development strategy with „surrogate“ endpoints at intermediate time-points and confirmatory approach post-licensing possible due to unmet medical need; placebo-control recommended.
- Patient population: Either Non-cirrhotic (fibrosis stage 2 and 3) or cirrhotic population; NASH diagnosis by histology (activity), or (cirrhotics) appropriate support of NASH with other factors.
- Non-cirrhotic population endpoint: Co-primary of histological evaluations of biopsies: „resolution of NASH without worsening of fibrosis“ and „improvement of fibrosis and no worsening of NASH“. Needs to be confirmed by hard endpoint data.
- Endpoints based on MoA: Possible, but if both co-primary EPs cannot be targeted, additional support needs to be presented (e.g. 2-stage fibrosis improvement in anti-fibrotics).
- Cirrhotic population endpoint: Reversal of cirrhosis. Potentially needs additional support and long-term outcome data. Other endpoints possible (e.g. MELD score improvement; HVPG improvement).
- Cirrhotic population with previous decompensation: Hard outcomes recommended (Decompensation events, LTx, death).
- Fixed duration of trials mentioned (although flexibility allowed)
- Combination treatment: Suitable for non-responder populations and those with high risk.
Stakeholder meeting Dec 2018:

- Has been presented within the Liver Forum 9 meeting

- Short summary of main points of discussion:
  - The request for co-primary endpoints is a too demanding requirement and one of the components may be important enough from the patient’s perspective
    - The request for co-primary endpoints is not adequate for certain MoA
  - The disharmonization of FDA and EMA requirements should be avoided
    - May unneccessarily prolong trial duration, and may take false conclusions
  - Requirements for combination therapy too strict
  - Need for development of PRO tools and inclusion of symptoms into trials not sufficiently addressed
  - Extend of CV safety documentation not clear
  - Paediatric issues: Presence of genetic factors, differences to adult disease, need for different endpoints
Written comments on Reflection paper:

- Total number of comments received: 19
- Total number of comments with regard to NASH parts: 15
- Stakeholder classification with comments on NASH:
  - 9 Industry (single company)
  - 1 Industry (association)
  - 2 Scientific organization/Learned society
  - 1 EU National regulatory agency
  - 1 Patient’s Advocacy Group/Organization
  - 1 Multistakeholder Organization
Written comments on Reflection paper:

- Comment areas:
  - General:
    - Separate into 2 (or even 3) guidance documents (1 comment)
    - Separate the three disease entities more clearly (2 comments)
    - Separate chapters for non-cirrhotic and cirrhotic populations (1 comment)
    - Separate non-compensated and compensated cirrhotic chapters more clearly (1 comment)

    - Clarify the terms „early and late clinical trials“ (2 comments)
    - Should be mentioned that agents regarded to act on the cause of the disease are more suitable than anti-fibrotics“ (1 comment)
    - Medical need in NASH should be discussed, also more from a CV perspective (1 comment)
    - Classification of fibrosis stages be adapted to AASLD classification (1 comment)
    - Estimand chapters should be more precise (1 comment)
    - Too much emphasis on the need for hard endpoints (1 comment)
    - Non-invasive diagnosis methods favoured/should be more promoted (1 comment)
Written comments on Reflection paper:

- **Comment areas:**
  - **Disease characterization:**
    - Oversimplification of pathophysiology should be avoided (1 comment)
  - **Inclusion criteria:**
    - Consider concomitant medication (and add-on medication during the trial) potentially influencing disease outcome (4 comments)
    - NASH diagnosis requirements based on NAS-requirements (NAS>5 and NAS>4 with additional requirements) too strict (3 comments)
    - Requirement for previously failed dietary treatment should be deleted or clarified/modified (2 comments)
    - Cirrhosis diagnosis should not be histological (but clinical) (2 comments)
    - Criteria for presence of features of the metabolic syndrome should be inclusion criteria (2 comments)
    - Simplify inclusion criteria and separate cirrhotic and non-cirrhotic (1 comment)
    - NASH-cirrhosis diagnosis should be more flexible (1 comment)
    - Severity of cirrhosis should be classified according to established criteria (e.g. Child Pugh) (1 comment)
Regulatory interaction: Written comments

Written comments on Reflection paper:

- Comment areas:
  - Trial design/Endpoints:
    - The request for co-primary evaluation of the two composites too strict (11 comments)
    - The request for 2-stage improvement of fibrosis in antifibrotics is too strict (6 comments)
    - Symptoms (PROs) and evaluation of QoL should be included (6 comments)
    - The study duration should be given as „flexible“ only (5 comments)
    - Combination therapy requirements too strict (not only 2\textsuperscript{nd} line and „at risk populations“) (5 comments)
    - Requirement for histology in „early“ trials should be deleted (4 comments)
    - Include „manifestation of T2DM“ (1 comment) and CV MACE (3-component) events in the „hard endpoints“ (2 comments)
    - Replace requirement for „MELD>14“ with „MELD>15“ (2 comments)
    - Reversal of cirrhosis should be classified as „hard endpoint“ (1 comment) or be recognized intermediate endpoint without restrictions (3 comments)
    - Manifestation of cirrhosis should be defined as „hard endpoint“ (1 comment)
Written comments on Reflection paper:

- Comment areas:
  - Trial design/Endpoints (continued):
    - Mention the use of special design features (e.g. adaptive design, extrapolation of placebo-control) for development of combination treatments (1 comment)
    - Suitability of MELD for a patient population with CV disease be checked (1 comment)
    - Allow more flexibility with regard to definition of „resolution of NASH“ especially with regard to the ballooning criteria (2 comments) or the steatosis criterion (1 comment)
  - Safety:
    - Clarify/State that CV outcome trials are not required for documentation of safety (3 comments)
    - It should be mentioned that treatments have no detrimental effect on other aspects of the metabolic syndrome (T2DM, obesity, serum lipids)
Written comments on Reflection paper:

- Comment areas:
  - Children:
    - Age cut-off at 10 years proposed (1 comment)
    - Biomarkers should be primary endpoints (1 comment)
    - Histology as endpoint should not be mandatory (1 comment)
    - Histology as endpoint may be needed (1 comment)
    - Different histological features to be taken account of, different scoring system likely be needed (1 comment)
    - Young children (age 6-10) may not be candidates for pharmacological treatment (1 comment)
    - Studies in children (<12 years) should be deferred until more natural history data are available (1 comment)
EMA reflection paper: Future perspectives

- Schedule for finalization of the reflection paper currently unclear
- EMA still on "business continuity" and will move to "definite premises" at the end of the year only.
- Therefore only "rough estimation" can be given at this point of time:
  - Discussion in the Gastroenterology Drafting Group finalize end of 2019
  - Discussion within relevant EMA groups and CHMP: further 3-4 months
  - Publication of final paper: 2nd-3rd Quarter 2020
  - All comments will be published including acceptance and reasons

- Content to be reflected:
  - Co-primary endpoints to be abandoned? (in consequences also the requirement for 2-stage improvement of fibrosis in anti-fibrotic compounds).
  - 2 separate documents (one for NASH, one for PBC and PSC)
Thank you for your attention!